US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

CNS/Neurology Market Research Reports & Industry Analysis

RSS Feeds

CNS/Neurology Industry Research & Market Reports

3  4  5  6    8    10  11  12  
Partial Seizure-Pipeline Insights, 2016
1/1/2016 | published by: DelveInsight
... development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA ...  |  read more...
USD 1,250
Psychosis-Pipeline Insights, 2016
1/1/2016 | published by: DelveInsight
... Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. ...  |  read more...
USD 1,250
Recurrent Malignant Glioma-Pipeline Insights, 2016
1/1/2016 | published by: DelveInsight
... stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA ...  |  read more...
USD 1,250
Seizures-Pipeline Insights, 2016
1/1/2016 | published by: DelveInsight
... Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. ...  |  read more...
USD 1,250
Traumatic Brain Injury-Pipeline Insights, 2016
1/1/2016 | published by: DelveInsight
... stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA ...  |  read more...
USD 1,250
Cannabinoid Receptor Type 1 (CB1) Agonists -Pipeline Insights, 2016
1/1/2016 | published by: DelveInsight
... covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, ...  |  read more...
USD 1,250
Cannabinoid Receptor Type 1 (CB1) Antagonists -Pipeline Insights, 2016
1/1/2016 | published by: DelveInsight
... covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, ...  |  read more...
USD 1,250
Cannabinoid Receptor Type 2 (CB2) Agonists -Pipeline Insights, 2016
1/1/2016 | published by: DelveInsight
... covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, ...  |  read more...
USD 1,250
Autism-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
1/1/2016 | published by: DelveInsight
... objective of the Autism Report is to understand the market and pipeline status of the drugs around the Autism to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline ...  |  read more...
USD 2,000
Brain Tumor-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
1/1/2016 | published by: DelveInsight
... key objective of the Brain Tumor Report is to understand the market and pipeline status of the drugs around the Brain Tumor to explore the generic development opportunities, licensing opportunities and to gain competitive advantage ...  |  read more...
USD 2,000
Fibromyalgia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
1/1/2016 | published by: DelveInsight
... objective of the Fibromyalgia Report is to understand the market and pipeline status of the drugs around the Fibromyalgia to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline ...  |  read more...
USD 2,000
Glioblastoma Multiforme (GBM)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
1/1/2016 | published by: DelveInsight
... A key objective of the Glioblastoma Multiforme (GBM) Report is to understand the market and pipeline status of the drugs around the Glioblastoma Multiforme (GBM) to explore the generic development opportunities, licensing opportunities and to ...  |  read more...
USD 2,000
Glioma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
1/1/2016 | published by: DelveInsight
... objective of the Glioma Report is to understand the market and pipeline status of the drugs around the Glioma to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline ...  |  read more...
USD 2,000
Malignant Glioma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
1/1/2016 | published by: DelveInsight
... key objective of the Malignant Glioma Report is to understand the market and pipeline status of the drugs around the Malignant Glioma to explore the generic development opportunities, licensing opportunities and to gain competitive advantage ...  |  read more...
USD 2,000
Medulloblastoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
1/1/2016 | published by: DelveInsight
... objective of the Medulloblastoma Report is to understand the market and pipeline status of the drugs around the Medulloblastoma to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline ...  |  read more...
USD 2,000
Restless Legs Syndrome-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
1/1/2016 | published by: DelveInsight
... A key objective of the Restless Legs Syndrome Report is to understand the market and pipeline status of the drugs around the Restless Legs Syndrome to explore the generic development opportunities, licensing opportunities and to ...  |  read more...
USD 2,000
Tourette Syndrome-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
1/1/2016 | published by: DelveInsight
... key objective of the Tourette Syndrome Report is to understand the market and pipeline status of the drugs around the Tourette Syndrome to explore the generic development opportunities, licensing opportunities and to gain competitive advantage ...  |  read more...
USD 2,000
Depression - Pipeline Review, H2 2015
11/30/2015 | published by: Global Markets Direct
... Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It ...  |  read more...
USD 2,000
Migraine - Pipeline Review, H2 2015
12/16/2015 | published by: Global Markets Direct
... Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It ...  |  read more...
USD 2,000
Partial Seizure - Pipeline Review, H2 2015
12/16/2015 | published by: Global Markets Direct
... therapeutic development for Partial Seizure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
USD 2,000
Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2015
12/23/2015 | published by: Global Markets Direct
... information on the therapeutic development for Amyotrophic Lateral Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest ...  |  read more...
USD 2,000
Schizophrenia - Pipeline Review, H2 2015
12/23/2015 | published by: Global Markets Direct
... Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It ...  |  read more...
USD 2,000
Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2015
12/23/2015 | published by: Global Markets Direct
... report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule ...  |  read more...
USD 2,000
Global and Chinese Ziprasidone Mesylate Industry, 2016 Market Research Report
1/20/2016 | published by: Prof-Research
... market. The report provides key statistics on the market status of the Ziprasidone Mesylate manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.Firstly, the report provides ...  |  read more...
USD 2,900
Cerebral Infarction (Brain Infarction) Global Clinical Trials Review, H2, 2015
12/16/2015 | published by: GlobalData
... trials scenario. This report provides top line data relating to the clinical trials on Cerebral Infarction (Brain Infarction). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the ...  |  read more...
USD 2,500
3  4  5  6    8    10  11  12